Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

18.20USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$18.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
260,190
52-wk High
$36.80
52-wk Low
$18.00

Latest Key Developments (Source: Significant Developments)

Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals
Monday, 15 May 2017 12:38pm EDT 

May 15 (Reuters) - AMAG Pharmaceuticals Inc ::Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing.  Full Article

Amag Pharmaceuticals Inc says increased size of offering to $300 mln
Friday, 5 May 2017 07:00am EDT 

May 5 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces pricing of $300 million of 3.25% convertible senior notes due 2022.Amag Pharmaceuticals Inc- amag has increased size of offering from originally announced $250 million.  Full Article

AMAG Pharma announces proposed offering of $250 mln of convertible senior notes due 2022
Wednesday, 3 May 2017 04:17pm EDT 

May 3 (Reuters) - AMAG Pharmaceuticals Inc :AMAG Pharmaceuticals Inc announces proposed offering of $250 million of convertible senior notes due 2022.AMAG Pharmaceuticals Inc says notes will pay interest semiannually and will mature on june 1, 2022.AMAG Pharmaceuticals Inc -intends to use net proceeds from offering of notes together with cash on hand to repay approximately $320.8 million of borrowings.AMAG Pharmaceuticals Inc says may enter into privately negotiated transactions with certain holders of its existing 2.50% convertible senior notes due 2019.  Full Article

AMAG Pharmaceuticals posts Q1 loss per share $1.06
Tuesday, 2 May 2017 07:01am EDT 

May 2 (Reuters) - AMAG Pharmaceuticals Inc :AMAG Pharmaceuticals announces first quarter 2017 financial results and provides corporate update.Q1 loss per share $1.06.Q1 earnings per share view $1.64 -- Thomson Reuters I/B/E/S.Q1 revenue $139.5 million versus I/B/E/S view $152.4 million.AMAG Pharmaceuticals Inc sees 2017 revenue between $625 million and $685 million.  Full Article

AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - AMAG Pharmaceuticals Inc :Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study.Achieved all primary and secondary safety and efficacy endpoints.On track to file SNDA mid-year with a potential approval and launch in first half of 2018.Expects to file a supplemental nda with u.s. Fda by mid-2017 to potentially broaden use of feraheme.  Full Article

Amag submits supplemental NDA for makena auto-injector
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Amag Pharmaceuticals Inc :Amag submits supplemental new drug application to FDA for makena (hydroxyprogesterone caproate injection) auto-injector for subcutaneous use.Anticipates a six-month FDA review timeline with potential for approval and launch in Q4 of 2017.Amag Pharmaceuticals - if makena auto-injector is approved, Amag will request orange book listing of eligible antares patents, last of which expires in 2026.  Full Article

Amag Pharmaceuticals, Endoceutics enter into license agreement
Tuesday, 14 Feb 2017 07:00am EST 

Amag Pharmaceuticals Inc : Amag and Endoceutics enter into an exclusive U.S. license agreement for intrarosa™ (prasterone) . Amag Pharmaceuticals Inc says "Endoceutics plans to put an additional $20 million toward supporting educational programs in 2017" . Amag Pharmaceuticals Inc- Amag expects to launch intrarosa in U.S. In mid-2017 .Amag Pharma-under terms of deal, at closing, co to pay endoceutics $50 million of total consideration, issue endoceutics 600,000 unregistered shares of co.  Full Article

Amag Pharmaceuticals enters into an agreement to develop and commercialize Rekynda
Monday, 9 Jan 2017 08:00am EST 

Amag Pharmaceuticals Inc : Entered into an agreement for exclusive North American rights to develop and commercialize Rekynda . Anticipated filing date in U.S. for NDA for Rekynda is in early 2018, with an anticipated approval and launch by early 2019 . Under terms of license agreement, Amag will pay to Palatin $60 million of total upfront consideration .To reimburse palatin for up to $25 million of ongoing development expenses incurred by Palatin related to development of Rekynda in 2017.  Full Article

Amag Pharmaceuticals qtrly loss per share $0.02
Tuesday, 9 Aug 2016 07:30am EDT 

Amag Pharmaceuticals Inc : Amag Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Qtrly loss per share $0.02 . Q2 earnings per share view $1.20, revenue view $128.5 million -- Thomson Reuters I/B/E/S . Fy2016 revenue view $533.8 million -- Thomson Reuters I/B/E/S . Total gaap quarterly product and service revenues increased approximately 50% to $127 million . Amag pharmaceuticals inc says total product and service revenue for q2 of 2016 increased approximately 50% to $127.4 million . Sees fy 2016 gaap total revenue $503 million - $553 million . Sees fy 2016 non gaap total revenue $520 - $570 million .Sees fy 2016 gaap net income $0 - $30 million ; sees fy 2016 non gaap net income $195 - $225 million.  Full Article

Amag Pharma- FDA provides manufacturing update on Makena
Friday, 22 Jul 2016 06:04am EDT 

Amag Pharmaceuticals Inc : Notified by FDA that prior approval supplement for coldstream labs approved for manufacture of preservative-free formulation of Makena .Approval provides company with an alternative manufacturer for single-dose formulation of Makena.  Full Article

More From Around the Web

BRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals

* Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing Source text (http://bit.ly/2rj6Y6h) Further company coverage: